{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T08:48:51Z","timestamp":1678438131237},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.7347","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T23:26:51Z","timestamp":1481758011000},"page":"3595-3601","source":"Crossref","is-referenced-by-count":5,"title":["Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions"],"prefix":"10.2169","volume":"55","author":[{"given":"Yuichi","family":"Miyashima","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Honma","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Oe","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Senju","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Hiura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Abe","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Harada","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58: 655-662, 2013.","DOI":"10.1016\/j.jhep.2012.09.037"},{"key":"2","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"2. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59: 2083-2091, 2014.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology 61: 400-401, 2015.","DOI":"10.1002\/hep.27559"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multination, phase 3, multicohort study. Lancet 384: 1597-1605, 2014.","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 58: 1555-1564, 2009.","DOI":"10.1136\/gut.2008.163675"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cacoub P, Bourli\u00e8re M, L\u00fcbbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 56: 455-463, 2012.","DOI":"10.1016\/j.jhep.2011.08.006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Biesbroeck LK, Scott JD, Taraska C, Moore E, Falsey RR, Shinohara MM. Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment. Am J Clin Dermatol 14: 497-502, 2013.","DOI":"10.1007\/s40257-013-0035-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chaiken BH, Goldberg BI, Segal JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 242: 897-898, 1950.","DOI":"10.1056\/NEJM195006082422304"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome\/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am 29: 481-501, 2009.","DOI":"10.1016\/j.iac.2009.04.007"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 55: 1-8, 2006.","DOI":"10.2332\/allergolint.55.1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by diagnostic scale of the international consensus meeting. Hepatol Res 192: 192-195, 2003.","DOI":"10.1016\/S1386-6346(03)00232-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 14: 6774-6785, 2008.","DOI":"10.3748\/wjg.14.6774"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Michielsen PP, Fierens H, Van Maercke YM. Drug-induced gallbladder disease. Incidence, aetiology and management. Drug Saf 7: 32-45, 1992.","DOI":"10.2165\/00002018-199207010-00005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kimura Y, Takada T, Strasberg SM, et al. TG13 current terminology, etiology, and epidemiology of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci 20: 8-23, 2013.","DOI":"10.1007\/s00534-012-0564-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Benm'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 88: 131-140, 2009.","DOI":"10.1097\/MD.0b013e3181a4d1a1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Figtree MC, Miyakis S, Tanaka K, Martin L, Konecny P, Krilis S. Dapsone hypersensitivity syndrome causing disseminated intravascular coagulation. BMJ Case Rep 2009 (in press).","DOI":"10.1136\/bcr.11.2008.1257"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Singhal R, Ganey PE, Roth RA. Complement activation in acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther 341: 377-385, 2012.","DOI":"10.1124\/jpet.111.189837"},{"key":"18","unstructured":"18. Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol 3: 333-340, 2006."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ellison RT, Horsburgh CR Jr, Curd J. Complement levels in patients with hepatic dysfunction. Dig Dis Sci 35: 231-235, 1990.","DOI":"10.1007\/BF01536768"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/24\/55_55.7347\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T05:57:37Z","timestamp":1498370257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/24\/55_55.7347\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":19,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.7347","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}